Search articles by title, topic or section.
Khabre desk
Recent reporting, analysis and explainers from the Clinical Research desk.
health
In the single-arm MDT-BRIDGE phase 2 study, 142 people with resectable or borderline resectable non-small-cell lung cancer received durvalumab plus chemotherapy before multidisciplinary teams directed them to surgery or chemoradiotherapy. Surgery was performed in 74.6%; survival follow-up is still early.
health
A randomized phase 2b trial compared the oncolytic adenovirus VCN-01 plus chemotherapy with chemotherapy alone as first-line treatment for metastatic pancreatic cancer. Progression-free survival was longer in the VCN-01 group, while overall-survival results differed between the trial’s analysis populations.
health
In a randomized phase 2 trial, evorpacept plus trastuzumab, ramucirumab and paclitaxel produced higher response rates than the same regimen without evorpacept. The trial met its prespecified response-difference threshold between treatment arms, but not its statistical target against a historical benchmark.
health
A South Korean phase 1b/2 trial found a 55% objective response rate when trastuzumab and nivolumab were added to gemcitabine and cisplatin for previously untreated HER2-positive advanced biliary tract cancer. The single-arm results provide early evidence for first-line HER2-targeted chemoimmunotherapy, while randomized confirmation is still needed.
health
A methylation-based blood test detected recurrence of non-viral head and neck cancer with 76.9% sensitivity and 94.6% specificity, and preceded clinical detection by a median of 131 days in 60% of cases where both occurred. Positive results were strongly associated with worse one-year survival.
health
A retrospective study of 2,396 people with advanced NSCLC found clinical-data AI models outperformed single biomarkers and helped physicians predict treatment response and survival.
health
In a randomized phase 2 trial, teclistamab produced deeper responses and longer progression-free survival than lenalidomide-dexamethasone in people with high-risk smoldering multiple myeloma. The study found high rates of complete response and minimal residual disease negativity after fixed-duration treatment.